logo
MPs Call for Gambling Law Review to Curb Harm

MPs Call for Gambling Law Review to Curb Harm

Medscape09-05-2025
MPs have urged the government to overhaul gambling laws to tackle gambling-related harm.
In a letter to Ashley Dalton, the minister in England responsible for overseeing health issues associated with gambling and other addictions, the Commons Health and Social Care Committee called for tougher regulations on gambling advertising, promotion, and sponsorship.
It cited serious harms linked to gambling, including financial, physical and mental health consequences.
Advertising Exposure and Normalisation
In an evidence session last month, the committee heard that gambling had become 'prevalent and normalised' in society, with 80% of the population being exposed to some form of gambling advertising on a weekly basis.
One academic witness described 'intrusive and targeted' promotions by gambling firms, with accounts of 'people receiving offers of free bets in the middle of the night', the letter said.
Committee chair Layla Moran MP recommended banning gambling ads before the 9 pm watershed, curbs on sports sponsorship, and restrictions on content designed to appeal to children and young people.
Gambling and Suicide Risks
Moran also noted evidence from the charity Gambling with Lives concerning the lack of public awareness about gambling harms, including suicide.
The 2023 National Suicide Prevention Strategy identified gambling as one of six factors linked to suicide at a population level. The committee highlighted evidence that an estimated 117 and 496 suicides were associated with problem gambling or gambling disorder in England in 2021-2022.
A lack of awareness amongst coroners of the link between gambling and suicide, and the fact that problem gambling, unlike smoking, alcohol, or drug use, was rarely recorded in an individual's medical notes meant that most gambling deaths were not properly investigated in a way that provided justice for families or that learns the vital lessons which could save lives, Moran stressed.
The letter called on the Department of Health and Social Care to outline what steps it would to raise awareness of suicides linked to problem gambling amongst coroners and others involved in the investigation of sudden deaths.
The committee recommended that the Office for Health Improvement and Disparities (OHID) should develop a public information campaign about gambling risks.
Problem Gambling in the Population
A 2023 review by Public Health England, whose public health functions have since been taken on by the OHID, estimated that 0.5% of the adult population had a problem with gambling, 3.8% were gambling at at-risk levels, and 7% were negatively impacted by another person's gambling.
Guidance from the National Institute for Health and Care Excellence earlier this year recommended that primary care clinicians should ask patients about their gambling habits.
A government spokesperson acknowledged receipt of the committee's letter and said it would formally respond in due course. In an emailed statement, the spokesperson added that the government recognised that gambling could be 'hugely damaging for people and their loved ones' and that it is 'committed to better protecting everyone from these harms'.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alligator Bioscience Provides Highlights from R&D Event 2025
Alligator Bioscience Provides Highlights from R&D Event 2025

Yahoo

time23 minutes ago

  • Yahoo

Alligator Bioscience Provides Highlights from R&D Event 2025

LUND, SE / / August 20, 2025 / Alligator Bioscience (Nasdaq Stockholm:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, provides key highlights from its R&D event held on 19 August 2025. The event featured presentations from Alligator's management and scientific leadership, outlining Alligator's clinical progress, upcoming milestones, and strategic outlook. Key takeaways from the event include: Mitazalimab - Phase 3 readiness : Long-term follow-up data continue to demonstrate encouraging overall survival in metastatic pancreatic cancer, supporting the confirmed regulatory path and planned initiation of a Phase 3 trial. Scientific insights : New translational biomarker data further expand and strengthen the rationale for mitazalimab in pancreatic cancer and other solid tumors, underscored by myeloid and T-cell activation and their correlation with improved clinical outcomes. Trial completion and CMC status: The final, 30-month, data read-out from OPTIMIZE-1 is expected during Q3 2025. The trial will thereafter be finalized, with mitazalimab being provided to patients still on treatment, and sites with ongoing patients remain open under limited, risk-based monitoring; manufacturing of Phase 3 material has been successfully completed. Investigator-initiated trials (IITs) : Based on the significant investigator interest Alligator is engaged in a number of externally funded exploratory and Phase 2 clinical trials with mitazalimab across pancreatic, gastrointestinal and other solid tumors to expand mitazalimab's future clinical use. Individual trials are expected to start during H2 2025 and the first half of 2026. Pipeline updates : The HER2 antibody HLX22 (developed by Chinese Henlius) has entered a global Phase 3 trial in gastric cancers. Alligator expects to receive the next development milestone within 6-12 months, and estimates that its share of the future royalties will amount to SEK 150-400 million annually. Strategic outlook : With a reduced burn-rate, Alligator is well positioned to advance mitazalimab into registrational trials together with a partner, and in parallel explore additional development options for the asset. Together mitazalimab and HLX22 represent a significant financial upside for Alligator. Other pipeline assets and technologies represent additional future development and income opportunities. A replay of the event is available through >>this link<< . For further information, please contact: Søren Bregenholt, CEOE-mail: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 12:15 p.m. CEST on 20 August 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit . Attachments Alligator Bioscience provides highlights from R&D event 2025 SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

UK regulator bans shower gel ad for perpetuating racial stereotypes
UK regulator bans shower gel ad for perpetuating racial stereotypes

CNN

time26 minutes ago

  • CNN

UK regulator bans shower gel ad for perpetuating racial stereotypes

UK regulators have banned a TV commercial for Sanex shower gel after ruling that it 'could be interpreted as suggesting that white skin was superior to black skin.' The Advertising Standards Authority (ASA) acted after receiving complaints about the ad from two people 'who believed the ad perpetuated negative stereotypes about people with darker skin tones,' it said in a statement Wednesday. The spot, which aired in June, featured a Black model whose skin is covered with red scratch marks and another covered with a cracked material that looks like clay. 'Try to take a shower with the new Sanex skin therapy and its patented amino acid complex. For 24-hour hydration feel,' a voice-over said, accompanying video of a White woman showering. 'Relief could be as simple as a shower,' it added. US consumer products company Colgate-Palmolive, which owns the Sanex brand, said the fact that the ad featured models with different skin tones demonstrated its commitment to diversity, according to the ASA's statement. The regulator said Colgate-Palmolive believed 'the depiction of diverse models in the ad, either experiencing skin discomfort or post-product relief, was utilised in a 'before and after' scenario to show their product was suitable and effective for all, rather than as a comparison based on race or ethnicity.' Clearcast, a company that checks whether TV commercials follow the UK Code of Broadcast Advertising before they can be aired, also said the ad demonstrated the inclusivity of Sanex. While the ASA accepted the argument that the ad showed 'before and after' scenarios to demonstrate the effectiveness of the product, it ruled that its structure was problematic. 'It was the black skin, depicted in association with itchy and dry skin, which was shown to be problematic and uncomfortable, whereas the white skin, depicted as smoother and clean after using the product, was shown successfully changed and resolved,' the statement said. 'That could be interpreted as suggesting that white skin was superior to black skin,' it added, while acknowledging that 'we understood that this message was not the one intended and might appear coincidental or pass unnoticed by some viewers.' The ASA added that it had concluded the ad had breached the broadcast advertising code and was likely to cause serious offense. CNN has contacted Colgate-Palmolive for comment.

'Much-loved' animal dies at zoo
'Much-loved' animal dies at zoo

Yahoo

timean hour ago

  • Yahoo

'Much-loved' animal dies at zoo

A "much-loved" animal has died at a zoo near Lowestoft. Jabu the African lion died earlier this week at Africa Alive in Kessingland. A spokesman for the zoo said: "We would like you to join us in celebrating the life of Jabu our much-loved male African lion, who sadly passed away under veterinary care this week. "Following ongoing veterinary care and regular observation due to age-related health changes, Jabu was recently diagnosed with advanced kidney disease. READ MORE: 'Sea of people' enjoy return of carnival parade "After careful consideration, and in line with established welfare protocols, our team made the kindest decision to ensure his comfort and well-being, preventing his condition from deteriorating further." Jabu was born in the zoo in 2009 and quickly became a firm favourite among staff, volunteers and visitors. "He leaves behind a lasting legacy, helping to engage millions of visitors in the challenges facing African lions and the importance of their conservation," the zoo added. "He was often seen playing alongside his sister Kaya and enjoying enrichment provided by his keepers, cardboard boxes being one of his favourites."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store